Yizhun Intelligence Completes Nearly 100 Million RMB Series B Financing, with T-Capital as Financial Advisor
On March 19, 2020, medical imaging AI company Beijing Yizhun Intelligence Technology Co., Ltd. (hereinafter referred to as “Yizhun Intelligence”) completed a nearly 100 million RMB Series B financing, with T-Capital acting as the financial advisor for this round.
This round was led by the Wondfo Biotech industry fund managed by Sanmei Investment, with co-investors including Xiaomiao Langcheng, and existing shareholders Hanergy Venture Capital and Qingsong Fund.
The proceeds from this round will be primarily used for product R&D and AI product line expansion, promoting the medical artificial intelligence detection system from a single organ to a single site and multiple diseases, and further strengthening Yizhun Intelligence’s product and commercialization capabilities in the field of medical imaging artificial intelligence.
For T-Capital, this project reflects its professional experience in healthcare financing, capital advisory for medical technology companies, and financing services for innovative medical projects.
Project Overview
| Item | Information |
|---|---|
| Company | Beijing Yizhun Intelligence Technology Co., Ltd. |
| Industry | Medical AI / Medical Imaging Artificial Intelligence |
| Financing Round | Series B |
| Financing Date | March 19, 2020 |
| Financing Size | Nearly 100 Million RMB |
| Lead Investor | Wondfo Biotech industry fund managed by Sanmei Investment |
| Co-investors | Xiaomiao Langcheng, Hanergy Venture Capital, Qingsong Fund |
| Financial Advisor | T-Capital |
| Use of Proceeds | Product R&D, AI product line expansion, and differentiated product development |
T-Capital Acts as Financial Advisor in This Round
In this financing, T-Capital acted as the financial advisor to Yizhun Intelligence, participating in the company’s financing transaction process and providing professional advisory support for the capital financing of medical AI companies.
For medical technology companies in a rapid development stage, financing is not only about obtaining funds, but also involves:
- Judging the company’s development stage;
- Designing a financing strategy;
- Screening investment institutions;
- Connecting with capital resources;
- Communicating corporate value;
- Promoting the financing process;
- Communicating with investors and executing the transaction.
Medical AI companies usually have multiple attributes of technology R&D, clinical application, product registration, and commercialization. Therefore, the financing process requires a combination of investment logic and industrial logic.
This Series B financing of Yizhun Intelligence also reflects the demand for professional capital services and industrial investment resources for healthcare companies after their technology products gradually enter the commercialization stage.
Yizhun Intelligence: Focusing on AI-Assisted Medical Image Diagnosis
Yizhun Intelligence, founded in November 2017, is a medical technology company specializing in artificial intelligence-assisted medical image diagnosis.
As early as 2014, members of the Yizhun Intelligence team began to study machine learning algorithms and tried to apply artificial intelligence technology to medical image-assisted diagnosis.
In the early days of the medical AI industry, this team had already begun to explore the combination of artificial intelligence and medical imaging.
During the “man-machine battle era” of the medical AI industry, the Yizhun Intelligence team participated in the international lung nodule detection competition LUNA16 and won the championship, becoming the first winning team in the Asia-Pacific region.
This technical accumulation became an important foundation for the company’s subsequent R&D of medical imaging AI products.
Expanding from a Single Disease to a Multi-Disease Medical Imaging AI
After its establishment, Yizhun Intelligence has continued to cultivate the clinical frontline and gradually formed a multi-product line layout.
The company has already launched:
- Intelligent detection system for pulmonary nodules;
- Intelligent detection system for breast mammography;
- Intelligent detection system for multiple lung diseases;
- Medical imaging artificial intelligence research platform.
Among them, the company has jointly built a medical imaging artificial intelligence research platform with IBM Watson - the Darwin Intelligent Research Platform.
According to information disclosed by Yizhun Intelligence at the time, the company’s products have been implemented in more than 400 hospitals across the country.
This commercialization foundation is also one of the important factors for investment institutions to pay attention to Yizhun Intelligence.
This Round of Financing Will Focus on Product R&D
According to the company, the proceeds from this round of financing will be focused on product R&D and further expanding the existing AI product line.
Yizhun Intelligence plans to promote the artificial intelligence detection system from single organ to single site disease coverage.
The company plans to develop artificial intelligence products for specific diseases based on different types of medical imaging equipment, including:
- CT;
- MR;
- Breast mammography machine;
- Ordinary X-ray machine;
- Ultrasound.
This means that the company’s product layout will be further expanded from a single imaging scenario to more equipment and diseases.
By combining different imaging equipment with AI algorithms, Yizhun Intelligence hopes to further expand the clinical application scenarios of medical imaging artificial intelligence technology.
Providing Customized AI Solutions for Strategic Partners
In addition to standardized product R&D, Yizhun Intelligence also plans to provide customized imaging AI detection systems for core strategic partners.
According to information disclosed by the company at the time, the company will provide differentiated product development and upgrade services based on the specific application scenarios of its partners.
This model combines standardized AI products with industrial cooperation, enabling medical AI technology to be developed for different medical scenarios.
For medical artificial intelligence companies, the balance between product standardization and scenario adaptation is an important issue in moving from technology R&D to large-scale commercialization.
Why Do Investment Institutions Pay Attention to Yizhun Intelligence?
This round of financing received participation from multiple investment institutions.
The lead investor, the Wondfo Biotech industry fund managed by Sanmei Investment, stated that medical AI is one of its key investment directions.
Sanmei Investment believes that against the backdrop of uneven distribution of high-quality medical resources and the accelerated implementation of hierarchical diagnosis and treatment, medical artificial intelligence has further application space in the medical field.
The investor also noted that although Yizhun Intelligence was established for a relatively short period of time, it has already formed a relatively rich product line and has made progress in product iteration, market expansion, and commercialization.
Xiaomiao Langcheng: Focusing on the Market Space of Medical Imaging AI
Co-investor Xiaomiao Langcheng stated at the time that the medical imaging AI industry has a large market space, and that single diseases also have the potential for further commercialization.
Xiaomiao Langcheng chose to invest in Yizhun Intelligence mainly because of the advantages of the founding team in industry understanding, industry resources, and talent resources.
At the same time, the investor also noted that the company has achieved commercialization more than two years after its establishment and has formed a certain foundation in terms of product line richness and installed base.
Qingsong Fund: Long-term Tracking of the Medical AI Industry
Liu Xiaosong, a partner at existing shareholder Qingsong Fund, said that Qingsong Fund has been continuously tracking the company since its seed round and has conducted long-term industry research.
In Qingsong Fund’s view, although Yizhun Intelligence was established later than some of its industry competitors, the company has developed rapidly and has formed product and commercialization capabilities in a short period of time.
Continuing to participate in this round of financing also reflects the continued attention of existing shareholders to the company’s subsequent development.
The Medical AI Financing Logic Reflected in the Yizhun Intelligence Project
From this financing, it can be seen that for medical AI companies to gain the attention of industrial capital and professional investment institutions, they usually need to meet multiple conditions, not just relying on the technology itself.
1. Technical Capabilities
Medical AI companies need to have stable algorithm R&D capabilities and be able to apply artificial intelligence technology to real medical scenarios.
2. Clinical Application
Medical AI products need to enter real hospitals and clinical environments to verify product value through practical application.
3. Product Capabilities
Companies need to transform technology into products that can be continuously iterated and commercialized, not just algorithms or laboratory results.
4. Commercialization Capabilities
Investment institutions will also pay attention to the number of hospitals where the product has been implemented, market expansion capabilities, and future commercialization space.
5. Product Line Expansion Capabilities
For medical AI companies, expanding from a single disease to multiple diseases, multiple devices, and more clinical scenarios is one of the important ways to expand commercialization space.
Yizhun Intelligence started with pulmonary nodule detection and gradually laid out breast mammography, multiple lung diseases, and other medical imaging scenarios, which reflects this development path.
From Financing to Industrial Development: What Kind of Capital Strategy Do Medical AI Companies Need?
Financing for healthcare companies is not just about solving short-term funding needs.
For companies in the product R&D and commercialization expansion stages, financing also serves several important functions:
Funding support, connection of industrial resources, acceleration of product commercialization, and upgrading of corporate strategy.
Especially for technology-based companies like medical AI, their development often requires simultaneous connection with:
- Medical institutions;
- Industrial capital;
- Medical device companies;
- Pharmaceutical companies;
- AI technology platforms;
- Investment institutions.
Therefore, investors and industrial partners who are suitable for the company’s development stage are also an important part of the financing strategy.
T-Capital: Focusing on Capital Transaction Services in the Healthcare Field
The Series B financing of Yizhun Intelligence is one of T-Capital’s case studies in serving the financing transactions of healthcare companies.
For healthcare companies seeking financing, the value of a professional financial advisor is not only in introducing investment institutions, but more importantly, in helping the company establish a clear financing logic and design a financing plan based on the company’s development stage, business model, product capabilities, and capital needs.
T-Capital focuses on the healthcare field, including:
- Innovative drugs;
- Medical devices;
- Medical AI;
- Medical imaging;
- Medical services;
- Medical diagnostics;
- High-value consumables;
- Biotechnology;
- Big health.
Based on the different development stages of companies, T-Capital can provide capital transaction advisory services including private financing, strategic financing, mergers and acquisitions, License & BD, strategic cooperation, and cross-border transactions.
If Your Company is Looking for Financing
For healthcare companies, when to finance, how much to finance, what type of investors to look for, and how to clearly explain the company’s technical and commercial value will all affect the financing efficiency and the final transaction result.
If your company is:
- Looking for Pre-A, A, B round or growth stage financing;
- Looking for medical industry capital;
- Looking for strategic investors;
- Raising funds for product commercialization;
- Planning to expand the R&D pipeline through financing;
- Looking for M&A or strategic cooperation opportunities;
- Exploring overseas capital and industrial resources;
You are welcome to communicate with T-Capital.
We can discuss suitable capital transaction paths based on your company’s development stage, financing goals, and industrial strategy.
→ Contact T-Capital to discuss your financing needs
Project Keywords
Yizhun Intelligence | Beijing Yizhun Intelligence Technology Co., Ltd. | Medical Imaging AI | AI-Assisted Diagnosis | Medical AI | Series B Financing | Nearly 100 Million RMB Financing | Financial Advisor | Healthcare Financing | Medical Imaging | AI Healthcare | Medical Technology | T-Capital
Frequently Asked Questions (FAQ)
When did Yizhun Intelligence complete its Series B financing?
Yizhun Intelligence completed a nearly 100 million RMB Series B financing on March 19, 2020.
Who was the financial advisor for Yizhun Intelligence’s Series B financing?
T-Capital acted as the financial advisor for this round.
Who were the investors in Yizhun Intelligence’s Series B financing?
The round was led by the Wondfo Biotech industry fund managed by Sanmei Investment, with co-investors including Xiaomiao Langcheng, and existing shareholders Hanergy Venture Capital and Qingsong Fund.
What kind of company is Yizhun Intelligence?
Yizhun Intelligence is a medical technology company specializing in artificial intelligence-assisted medical image diagnosis, founded in November 2017.
What medical AI products does Yizhun Intelligence have?
According to information disclosed by the company at the time, the company has launched an intelligent detection system for pulmonary nodules, an intelligent detection system for breast mammography, an intelligent detection system for multiple lung diseases, and has built a medical imaging artificial intelligence research platform.
How is the product implementation of Yizhun Intelligence?
According to information disclosed by the company at the time, its products have been implemented in more than 400 hospitals across the country.
What are the main uses of the proceeds from this round of financing for Yizun Intelligence?
The funds from this round will be mainly used for product R&D, expanding the AI product line, and promoting the artificial intelligence detection system from single organ to single site disease coverage.
What medical imaging equipment does Yizhun Intelligence plan to cover?
The company plans to develop artificial intelligence products for specific diseases based on various imaging equipment such as CT, MR, breast mammography machines, ordinary X-ray machines, and ultrasound.
What healthcare financing services does T-Capital provide?
T-Capital provides capital transaction advisory services for the healthcare sector, including private financing, strategic financing, mergers and acquisitions, License & BD, strategic cooperation, and cross-border transactions.
Why do healthcare companies need financial advisors for financing?
A professional financial advisor can help a company sort out its financing strategy, match it with investment institutions, establish a framework for communicating corporate value, and assist in promoting investor communication and transaction execution. The specific service content depends on the company’s development stage and transaction needs.